Remo CRO

News

New drug shows promise against several aggressive cancers

02.14 2019.

Initial trials in humans find that a new drug, tisotumab vedotin, shows significant promise in treating stubborn tumors in several late-stage cancers. Details

Merck Receives Breakthrough Therapy Designation from FDA for V114, the Company’s Investigational 15-Valent Conjugate Vaccine for the Prevention of Invasive Pneumococcal Disease, in Infants, Children, and Adolescents

02.09 2019.

KENILWORTH, N.J.–(BUSINESS WIRE) January 30, 2019 –Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that V114, the company’s investigational 15-valent pneumococcal conjugate vaccine, has received… Details

VLP Therapeutics Receives FDA Clearance of Investigational New Drug Application and Initiates First Clinical Trial of VLPM01 Malaria Vaccine

02.09 2019.

Gaithersburg, MD – February 4, 2019 —  VLP Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for a clinical trial of the Company’s VLPM01 malaria… Details

Biohaven Achieves Targeted Therapeutic Exposures of BHV-3500, a Third-Generation Small Molecule CGRP Receptor Agonist

02.09 2019.

NEW HAVEN, Conn., Feb. 4, 2019 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biotechnology company focused on advancing innovative therapies for neurological diseases, today announced that administration of intranasal… Details

Amgen And Allergan Announce Positive Top-Line Results From Phase 1/ Phase 3 Study Of ABP 798, Biosimilar Candidate To Rituximab

01.29 2019.

THOUSAND OAKS, Calif., Jan. 24, 2019 /PRNewswire/ — Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a Phase 1/ Phase 3 study evaluating the pharmacokinetics, efficacy and safety of biosimilar… Details

Theravance Biopharma Announces First Patient Dosed in Registrational Phase 3 Study of Ampreloxetine (TD-9855) for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension

01.29 2019.

DUBLIN, Jan. 28, 2019 /PRNewswire/ — Theravance Biopharma, Inc. (NASDAQ: TBPH) (“Theravance Biopharma” or the “Company”) today announced dosing of the first patient in a registrational Phase 3 clinical trial of ampreloxetine… Details